RELATIVE BIOAVAILABILITY OF COENZYME-Q10 FORMULATIONS IN HUMAN-SUBJECTS

The relative bioavailability of typical commercially available forms o f coenzyme Q10 (CoQ10) was compared with that of Q-Gel, a new solubili zed form of CoQ10, in human subjects in two separate trials. In the fi rst, standard softgel capsules containing CoQ10 suspension in oil, pow der-filled hardshell capsules and powder-based tablets were tested alo ng with Q-Gel using a daily dosage of 120 mg for three weeks. The base line plasma CoQ10 values were all very tight (0.50-0.52 mu g/mL) and a fter three weeks the values were 1.37, 1.63 and 1.60 mu g/mL for Q-Gel 22.86 (319%). The second trial, carried out to replicate the findings in the first, employed only two groups, namely the standard softgel c apsules containing the suspension and Q-Gel, and the duration was exte nded to four weeks. Plasma CoQ10 values were: 8.33 (100%) and 22.75 (2 73%). Thus, the data from both the trials show that Q-Gel, the new sol ubilized form of CoQ10, is vastly superior to typical commercially ava ilable preparations of CoQ10. This means much lower doses of Q-Gel wil l be required to rapidly reach and maintain adequate blood CoQ10 value s than with any of the other currently available products.